Lutris Pharma

Lutris Pharma is a clinical-stage biopharmaceutical company developing topical therapies to mitigate the cutaneous toxicity of anti-cancer treatments. Their lead asset, LUT014, aims to reduce EGFRi-induced acneiform rash, a common side effect that often leads to treatment discontinuation. This improves both patient quality of life and the efficacy of cancer therapies.

Buy Funded Startups lists

Funding Round: Series A

Funding Amount: $30M

Date: 28-Jan-2025

Investors: Columbus Venture Partners, Pontifax Venture Capital, Peregrine Ventures, aMoon Fund

Markets: Biopharmaceuticals, Oncology, Dermatology, Biotechnology, Drug Discovery

HQ: Tel Aviv, Israel

Founded: 2015

Website: https://www.lutris-pharma.com/

LinkedIn: https://www.linkedin.com/company/lutris-phama

Twitter:

Instagram: